Industry

Sobi and Bioverativ highlight commitment to improving care for people with haemophilia at ISTH 2017 congress

Swedish Orphan Biovitrum AB and Bioverativ Inc. today announces that new data from their extended half-life therapies, Alprolix® (eftrenonacog alfa)([Coagulation Factor IX (Recombinant), Fc Fusion Protein] and Elocta® (efmoroctocog alfa), marketed as ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein]) in the United States, Japan and Canada, will be presented at the International Society on Thrombosis […]

Read More